First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation

ASC4KIDS: investigating asciminib for pediatric patients with CMLПодробнее

ASC4KIDS: investigating asciminib for pediatric patients with CML

Debate: Chronic-Phase CML Patient Develops a T315I Mutation - Experimental TherapyПодробнее

Debate: Chronic-Phase CML Patient Develops a T315I Mutation - Experimental Therapy

Asciminib and bosutinib efficacy in CML-CP patients: a comparison studyПодробнее

Asciminib and bosutinib efficacy in CML-CP patients: a comparison study

ASCEMBL: asciminib versus bosutinib in third-line treatment of CP-CMLПодробнее

ASCEMBL: asciminib versus bosutinib in third-line treatment of CP-CML

ASC2ESCALATE: dose escalation study of asciminib in second-line CP-CMLПодробнее

ASC2ESCALATE: dose escalation study of asciminib in second-line CP-CML

ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemiaПодробнее

ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia

Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CMLПодробнее

Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CML

Phase I study of asciminib in patients with CP-CML carrying the T315I mutationПодробнее

Phase I study of asciminib in patients with CP-CML carrying the T315I mutation

Targeting TKI-resistant CML with LY3009120 and asciminibПодробнее

Targeting TKI-resistant CML with LY3009120 and asciminib

Case 2: Relapsed CML With T315I MutationПодробнее

Case 2: Relapsed CML With T315I Mutation

CML Overview | The National Leukemia Conference 2020Подробнее

CML Overview | The National Leukemia Conference 2020

Next generation TKIs for Ph+ ALLПодробнее

Next generation TKIs for Ph+ ALL

Simplab QLIMS - Batch ManufacturingПодробнее

Simplab QLIMS - Batch Manufacturing

Copy of Dr. Subramanian on the IMpower131 Trial in Squamous NSCLCПодробнее

Copy of Dr. Subramanian on the IMpower131 Trial in Squamous NSCLC

Addressing Current Questions and Controversies in the Management of Chronic Myeloid LeukemiaПодробнее

Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia

Case 2: Ponatinib for T315I-Mutated CMLПодробнее

Case 2: Ponatinib for T315I-Mutated CML

The use of asciminib versus ponatinib for multiresistant CMLПодробнее

The use of asciminib versus ponatinib for multiresistant CML

Detecting CML (Chronic Myeloid Leukemia) w/ Digital PCR | #LabChatПодробнее

Detecting CML (Chronic Myeloid Leukemia) w/ Digital PCR | #LabChat